

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Carfilzomib for treated multiple myeloma

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| No equality issues were identified at the scoping stage.  |

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| No other equality issues were identified in the submissions from either the experts or by the company.   |

- |  |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| No other quality issues identified.  |

- |  |
|--|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
|--|

No specific groups are excluded due to the recommendations of this appraisal.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No adverse impact on people with disabilities is expected.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No considerations needed by the committee as none were identified.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes within the summary table.

**Approved by Associate Director (name):** ...Frances Sutcliffe.....

**Date:** November 2016

## Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No equality issues were raised during the consultation period.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No barriers to entry for specific groups of people are expected with the new recommendations.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No adverse impacts are anticipated in people with disabilities.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No further recommendations needed as there were no equality issues identified during the consultation stage.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes provided in the summary table in section 4.

**Approved by Centre or Programme Director (name):** .....Frances Sutcliffe

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of carfilzomib for previously treated multiple myeloma

Issue date: May 2017

**Date:** 02/06/2017

## Final appraisal determination

(when no ACD was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

[Insert response here]

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

[Insert response here]

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

[Insert response here]

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

[Insert response here]

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

[Insert response here]

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

[Insert response here]

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

[Insert response here]

**Approved by Programme Director (name):** .....

**Date:** [xx/xx/year]